GTI-2040 Completed Phase 1 Trials for Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Recurrent Adult Acute Myeloid Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Treatment

Indications	Status	Purpose	Phase
DBCOND0036072 (Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)) DBCOND0036073 (Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)) DBCOND0028524 (Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities) DBCOND0036071 (Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)) DBCOND0028883 (Recurrent Adult Acute Myeloid Leukemia) DBCOND0028526 (Adult Acute Myeloid Leukemia With Inv(16)(p13;q22))	Completed	Treatment	1

clinicaltrials.gov Identifier	Title	Drugs
NCT00070551	GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	Cytarabine (DB00987) GTI-2040 (DB15030)